1.2 OMIM# of the disease 261540.
1.3 Name of the analysed genes or DNA/chromosome segments B3GALTL.
OMIM# of the gene(s)
610308.
Mutational spectrum
Fourteen variants that affect function have been reported, including 6 splicing variants, 4 nonsense variants, 3 missense variants, 1 frameshift variant, as well as 3 large deletions. The c.660+1G4A splicing variant is the most common variant identified. It accounts for 69% of all reported pathogenic alleles. 1 (www.lovd.nl/B3GALTL). The standard reference sequence indicating reported variants (ENSG00000187676) and a reference for exon numbering (ENST00000461652) can be found at http://www.ensembl.org.
Analytical methods
Sanger sequencing of the fifteen coding exons and flanking intronic sequences of the B3GALTL gene (NCBI reference sequence: NM_194318.3).
Analytical validation
Sanger sequencing identifies variants in 499% of patients. Deep intronic variants, large deletions and duplications would not be detected using this approach. Novel variants with uncertain pathogenic nature are of course possible.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence. If known to be a variable between ethnic groups, please report):
The total number of reported patients with Peters plus syndrome due to B3GALTL variants is 49 (belonging to 40 families). [1] [2] [3] The frequency and the prevalence of the disease are not known.
Diagnostic setting
The term 'Peters'-plus syndrome' was first proposed in 1984 by van Schooneveld et al. 4 The underlying defect (mutations in B3GALTL coding for O-fucose-specific β-1,3-glucosyltransferase) was identified in 2006. [5] [6] [7] B3GALTL is involved in the synthesis of the unusual O-linked disaccharide glucosyl-beta-1,3-fucose-O-attached to the thrombospondin type 1 repeats (TSRs) of many important proteins. The biosynthesis of this disaccharide is initiated by protein-O-fucosyltransferase 2, which attaches the fucosyl residue to a serine or threonine within the TSR. B3GALTL subsequently transfers the glucose onto TSR-fucose. This disorder thus belongs to the protein O-glycosylation defects, subgroup O-fucosylglycan synthesis defects. Peters plus syndrome due to defective B3GALTL is an autosomal recessive disorder. Constant features are anterior chamber eye abnormalities and rhizomelic limb shortening. The most common anterior chamber eye defect is Peters' anomaly. It comprises central corneal clouding, thinning of the posterior cornea and iridocorneal adhesions, and is usually bilateral. Its expression ranges from mild to severe. Lens abnormalities (cataracts, congenital glaucoma) are associated with the severe form. Growth retardation starts prenatally, and in some patients there is also growth hormone deficiency that responds well to growth hormone treatment. In the majority of patients, there is variable developmental delay/intellectual disability, as well as craniofacial dysmorphism (variable combinations of a prominent forehead, a broad neck, short palpebral fissures, a long filtrum, an exaggerated Cupid's bow of the vermilion of the upper lip, a cleft lip, a cleft palate and ear anomalies). Less frequent findings are brain, heart and urogenital malformations. A few patients have been reported with congenital hypothyroidism or conductive hearing loss. No phenotypegenotype correlation could be found. No biochemical markers have been identified; serum apo C-III and serum transferrin isoelectrofocusing show a normal pattern. The diagnosis has to be confirmed by mutation analysis of B3GALTL. No B3GALTL mutations have been found in Peters plus syndrome-like phenotypes or in isolated Peters' anomaly. An upcoming strategy, in case of clinical suspicion of Peters plus syndrome, is to subject the DNA to a panel of genes known to be involved in CDG. The identification of the pathogenic variant(s) will permit heterozygote detection in the family and prenatal diagnosis. 
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
There is no other test to confirm the diagnosis in a patient than molecular genetic testing.
Analytical specificity (proportion of negative tests if the genotype is not present)
See 2.1.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case-by-case.
The proportion of B3GALTL mutations is close to 100% in patients with classic Peters plus syndrome.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case-by-case.
In the absence of classic Peters plus syndrome, the proportion of B3GALTL mutations is nearly 0%.
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
100%, based on the presence of B3GALTL mutations.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: 100%. Index case in that family had not been tested: 100%. 3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.9 'C' was marked) 3.3.1 Does the result of a genetic test resolve the genetic situation in that family? Usually yes, by testing the potential heterozygous persons (carriers) in the family.
